Dab Igatran 150 mg
Dabigatran Etexilate Capsule, Coated Pellets
Product Images NDC 67877-474
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Dabigatran Etexilate (NDC 67877-474). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Dab Igatran 75 mg
Each capsule contains 86.48 mg dabigatran etexilate mesylate, which is equivalent to 75 mg dabigatran etexilate. The usual dosage is included in the package insert. The capsules should be stored at a temperature of 20°C to 25°C (68°F to 77°F) with limited excursions to 15°C to 30°C (59°F to 86°F) and in the original package to protect from moisture. The product should be used within 4 months of opening. The medication guide is enclosed in the unit of use container. Notable ingredients include FD&C Yellow No.6 as a color additive. The drug is distributed by Ascond Laboratories and manufactured by Akem Laboratories Ltd in India. Keep the bottle tightly closed and out of reach of children.*
Dab Igatran Fig1
Dab Igatran Fig2
The text seems to be a chart or graph showing the aPTT (activated partial thromboplastin time) time course for a medication called Dabigatran. It includes dosages of 160mg and 75mg based on the patient's G101 and G201 levels. However, without further context or explanation, it's difficult to fully understand the chart's purpose.*
Dab Igatran Fig3 1
Dab Igatran Fig3 2
Dab Igatran Fig4
Dab Igatran Fig5
Dab Igatran Structure
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
